QUALCOMM (QCOM) Launches Snapdragon Reality Elite For On Device AI And Mixed Reality

  • QUALCOMM has launched its Snapdragon Reality Elite platform, targeting on-device AI and spatial computing for mixed reality and immersive devices.
  • The move signals an expansion beyond smartphones into hardware designed for spatial computing experiences.
  • This product aims to support new use cases in mixed reality, including wearables and other immersive form factors.

QUALCOMM, traded as NasdaqGS:QCOM, is adding Snapdragon Reality Elite to its lineup at a time when the stock is priced at $178.1. The share price reflects a mixed recent stretch, with the stock down 2.7% over the past week and down 15.9% over the past month, while still up 17.9% over the past year.

For investors tracking how QUALCOMM is using its AI capabilities, this move into spatial computing hardware and on-device AI marks an effort to build beyond its core smartphone franchise. The launch of Snapdragon Reality Elite introduces another way the company can participate in device categories tied to mixed reality and immersive experiences.

Stay updated on the most important news stories for QUALCOMM by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on QUALCOMM.

NasdaqGS:QCOM Earnings & Revenue Growth as at Jul 2026
NasdaqGS:QCOM Earnings & Revenue Growth as at Jul 2026

3 things going right for QUALCOMM that this headline doesn't cover.

Advertisement

Quick Assessment

  • ✅ Price vs Analyst Target: QUALCOMM trades at US$178.1, around 19.7% below the US$221.9 analyst target.
  • ⚖️ Simply Wall St Valuation: The stock is described as trading close to estimated fair value.
  • ❌ Recent Momentum: The share price has declined 15.9% over the past 30 days.

There's only one way to know the right time to buy, sell or hold QUALCOMM. Head to Simply Wall St's company report for the latest analysis of QUALCOMM's Fair Value.

Key Considerations

  • 📊 Snapdragon Reality Elite positions QUALCOMM further in on-device AI and mixed reality hardware, which may diversify its revenue drivers beyond smartphones.
  • 📊 Monitor adoption of spatial computing devices, management commentary on this platform, and how much of QUALCOMM's earnings still depend on handset cycles.
  • ⚠️ Recent share price volatility and flagged insider selling suggest it may be prudent to pay close attention to risk disclosures and trading activity around this launch.

Dig Deeper

For the full picture including more risks and rewards, check out the complete QUALCOMM analysis. Alternatively, you can check out the community page for QUALCOMM to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if QUALCOMM might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:QCOM

QUALCOMM

Engages in the development and commercialization of foundational technologies for the wireless industry worldwide.

Flawless balance sheet established dividend payer.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
186 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0